Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study

• Published in: European journal of heart failure Vol. 26; no. 8; pp. 1736 - 1744
• Main Authors: Allach, Youssra, Barry‐Loncq de Jong, Mylene, Clephas, Pascal R.D., Gent, Marco W.F., Brunner‐La Rocca, Hans‐Peter, Szymanski, Mariusz K., Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E.M., Asselbergs, Folkert W., Kimmenade, Roland R.J., Manintveld, Olivier C., Mieghem, Nicolas M.D.A., Beeres, Saskia L.M.A., Rienstra, Michiel, Post, Marco C., Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C.M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D.J., Ramshorst, Jan, Kirchhof, Charles J.H.J., Feenema‐Aardema, Margriet W., Fonseca, Carlos A., Heuvel, Mieke, Hazeleger, Ronald, Eck, J.W. Martijn, Boersma, Eric, Kardys, Isabella, Boer, Rudolf A., Brugts, Jasper J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01-08-2024
• Subjects: Biomarkers; Haemodynamic monitoring; Heart failure; Intracardiac pressures; Repeated measurements; Risk stratification; Heart failure; Biomarkers; Risk stratification; Intracardiac pressures; Haemodynamic monitoring; Repeated measurements
• DOI: 10.1002/ejhf.3303
• EISSN: 1879-0844
• ISSN: 1388-9842; 1879-0844

Aims
Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms.
Methods
The BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death.
Conclusion
Since the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.
Design and rationale of the BioMEMS study. QoL, quality of life. Graphical is created with BioRender.com